Introduction
Methods
Search strategy
Data extraction and quality assessment
Data analysis
Results
Study selection
Study characteristics
CAT [30] | AMIOVIRT [31] | DEFINITE [32] | COMPANION [33] | SCD-HeFT [3] | DANISH [6] | |
---|---|---|---|---|---|---|
Author | Bansch et al. | Strickberger et al. | Kadish et al. | Bristow et al. | Bardy et al. | Kober et al. |
Year of publication | 2002 | 2003 | 2004 | 2004 | 2005 | 2016 |
Enrolment period | 1991–1997 | 1996–2000 | 1998–2002 | 2000–2002 | 1997–2001 | 2008–2014 |
Number of patients | 104 | 103 | 458 | 1,520 | 2,521 | 1,116 |
Control group | MT | Amiodarone + MT | MT | MT | Placebo (MT) or amiodarone + MT | MT or MT + CRT‑P |
Inclusion criteria | DCM LVEF ≤ 30% NYHA class II–III | DCM LVEF ≤ 35% NYHA class I–III NSVT | niCMP LVEF ≤ 35% NYHA class I–III NSVT or PVC | iCMP and niCMP LVEF ≤ 35% NYHA class III–IV QRS > 120 ms | iCMP and niCMP LVEF ≤ 35% NYHA class II–III | niCMP LVEF ≤ 35% NYHA class II–IV NT-pro BNP > 200 |
Exclusion criteria regarding CMP | Myocarditis HCM Restrictive CMP | Familial CMP Congenital HD | Infiltrative CMP HCM | Infiltrative CMP HCM Myocarditis Congenital HD | Myocarditis HCM Congenital HD Constrictive pericarditis | |
Primary endpoint | All-cause mortality | All-cause mortality | All-cause mortality | Composite of all-cause mortality or hospitalisation for any cause | All-cause mortality | All-cause mortality |
Follow-up (years) | 2.0 | 2.2 | 2.4 | 1.3 | 3.8 | 5.6 |
Crossover | n. r. | Yes | Yes | Yes | Yes | Yes |
ITT analysis | Yes | Yes | Yes | Yes | Yes | Yes |
CAT | AMIOVIRT | DEFINITE | COMPANION | SCD-HeFT | DANISH | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MT | ICD | MT | ICD | MT | ICD | MT | CRTP | CRTD | Placebo | Amio | ICD | MT | ICD | |
Enrolled patients (n) | 54 | 50 | 52 | 51 | 229 | 229 | 308 | 617 | 595 | 847 | 845 | 829 | 560 | 556 |
Patient characteristics | ||||||||||||||
Age, years | 52 | 52 | 60 | 58 | 58 | 58 | 68 | 67 | 66 | 60 | 60 | 60 | 63 | 64 |
Male | 77 | 86 | 74 | 67 | 70 | 73 | 69 | 67 | 67 | 77 | 76 | 77 | 72 | 73 |
AF | 11 | 20 | n. r. | n. r. | 26 | 23 | n. r. | n. r. | n. r. | 14 | 16 | 17 | 20 | 24 |
niCMP | 100 | 100 | 100 | 100 | 100 | 100 | 41 | 46 | 45 | 47 | 50 | 48 | 100 | 100 |
Duration of HF, years | 2.5 | 3 | 1.8 | 2.2 | 3.3 | 2.4 | 4.9 | n. r. | 4.4 | n. r. | n. r. | n. r. | 1.5 | 1.7 |
LVEF, % | 25 | 24 | 23 | 22 | 22 | 21 | 22 | 20 | 22 | 25 | 25 | 24 | 25 | 25 |
NYHA class | ||||||||||||||
– I | 13 | 18 | 18 | 25 | ||||||||||
– II | 64 | 67 | 63 | 64 | 61 | 54 | 70 | 71 | 68 | 54 | 53 | |||
– III | 36 | 33 | 24 | 16 | 21 | 21 | 82 | 87 | 86 | 30 | 29 | 32 | 46 | 47 |
QRS duration, ms | 114 | 102 | n. r. | n. r. | 116 | 115 | 158 | 160 | 160 | n. r. | n. r. | n. r. | 145 | 146 |
CRT | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100 | 100 | 0 | 0 | 0 | 57 | 58 |
Pharmacological therapy | ||||||||||||||
Amiodarone | n. r. | n. r. | 100 | 0 | 7 | 4 | 55 | n. r. | 55 | n. r. | 100 | n. r. | 6 | 6 |
Betablocker | 4 | 4 | 50 | 53 | 84 | 86 | 66 | 68 | 68 | 69 | 69 | 69 | 92 | 92 |
ACE/ARB | 98 | 94 | 81 | 90 | 96 | 97 | 89 | 89 | 90 | 98 | 97 | 94 | 97 | 96 |
MRA | n. r. | n. r. | 19 | 20 | n. r. | n. r. | 55 | 53 | 55 | n. r. | n. r. | 20 | 57 | 59 |